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THIS ISSUE’S AUTHORS 
LINDA A. DIMEFF, PH.D., is a chief sci­
entific officer at Behavioral Tech Research, 
Inc., a research organization dedicated to 
the dissemination of evidence-based prac­
tices (EBPs). She is also a clinical instructor 
in the Department of Psychology at the Uni­
versity of Washington. Her research inter­
ests include EBPs, addictive behaviors, dialec­
tical behavior therapy (DBT), and the 
adaptation of DBT for substance-depend­
ent individuals with borderline personality 
disorder. She has received four technology 
transfer grants from NIDA to disseminate 
DBT. Dr. Dimeff is the primary editor of 
Dialectical Behavior Therapy in Clinical Prac­
tice: Applications Across Disorders and Set­
tings (2007). 
KYLE M. KAMPMAN, M.D., is a board-
certified psychiatrist specializing in addic­
tion psychiatry. He is currently the medical 
director of the Charles O’Brien Center for 
the Treatment of Addictions, and an asso­
ciate professor of psychiatry and the med­
ical director of the University of Pennsyl­
vania Treatment Research Center in 
Philadelphia. His research interests include 
pharmacotherapy for cocaine dependence 
and the cocaine withdrawal syndrome. He 
is currently engaged in a study of topiramate 
as a treatment for comorbid alcohol and 
cocaine dependence. He also serves on the 
editorial board of the Journal of Addiction 
Medicine. 
KENNETH L. KIRSH, PH.D., is an assis­
tant professor in the Department of Phar­
macy Practice and Science at the University 
of Kentucky and a licensed clinical psy­
chologist. He has authored publications on 
the assessment and management of pain, 
the relationship of pain to abuse and addic­
tion, and symptom management in can­
cer populations. He chairs the Hospice of 
the Bluegrass Research Committee and the 
Pain Treatment Center of the Bluegrass Pain 
Committee. 
MARSHA M. LINEHAN, PH.D., is a pro­
fessor of psychology at the University of 
Washington; the founder of both the Marie 
Institute of Behavioral Technology and 
Behavioral Tech, LLC, a treatment dissem­
ination company; and director of the Behav­
ioral Research and Therapy Clinics. Her 
research involves applying behavioral mod­
els to the treatment of suicidality, drug abuse, 
and borderline personality disorder, as well 
as finding ways to transfer effective treat­
ment methods from the academic to the 
clinical community. She is the author of 
numerous research articles, books, and treat­
ment manuals. 
STEVEN D. PASSIK, PH.D., is an asso­
ciate attending psychologist in the Depart­
ment of Psychiatry and Behavioral Sciences 
at the Memorial Sloan-Kettering Cancer 
Center. He has treated people with cancer 
for nearly 20 years, and his work has focused 
on the psychological aspects of cancer, includ­
ing palliative care, symptom management, 
pain, depression, nausea, and fatigue. He 
has written and published extensively on 
the interface of pain management and addic­
tion. 
SEDDON R. SAVAGE, M.D., M.S., is a 
clinician, educator, and policy consultant 
in the fields of addiction and pain medicine; 
an associate professor of anesthesiology at 
the Dartmouth Medical School; and the 
director of the Dartmouth Center on Addic­
tion Recovery and Education. She has held 
a number of national leadership positions 
in the fields of addiction and pain medicine, 
and is currently president of the New Hamp­
shire Medical Society. She has published 
numerous journal articles and book sections, 
as well as a textbook on addiction medicine. 
& PANEL RESPONDENTS 
MICHAEL P. BOGENSCHUTZ, M.D., 
is a professor of psychiatry and the vice-chair 
for addiction psychiatry at the University 
of New Mexico Health Sciences Center and 
Center on Alcoholism, Substance Abuse, 
and Addictions in Albuquerque, New Mex­
ico. He also directs the Addiction Psychia­
try Fellowship Program in the Department 
of Psychiatry. Dr. Bogenschutz heads a pro­
gram of clinical research in addiction treat­
ment that includes federally funded studies 
of novel pharmacological and behavioral 
therapies for drug and alcohol addiction and 
co-occurring disorders. He is the principal 
investigator of the Southwest Node of the 
NIDA Clinical Trials Network.  
LAWRENCE J. DeMARZO is the execu­
tive director of House of the Crossroads in 
Pittsburgh, Pennsylvania. House of the Cross­
roads employs a community-based and -ori­
ented collaborative approach to drug abuse 
treatment service delivery, using the Ther­
apeutic Community Model, and provides 
a comprehensive continuum of care. Mr. 
DeMarzo serves as the community treat­
ment provider representative for the 
Appalachian Tri-State Node of the NIDA 
Clinical Trials Network. He has extensive 
experience with development, implemen­
tation, and collaboration of human services 
in community-based settings. 
MARDELL GAVRIEL, PSY.D., is the man­
aging director of mental health at Walden 
House, a behavioral health agency provid­
ing integrated substance abuse and mental 
health treatment to underserved popula­
tions in California. Dr. Gavriel is a licensed 
psychologist who came to Walden House 
after earning a doctorate in clinical psy­
chology from the Chicago School of Pro­
fessional Psychology in 1997. She has devel­
oped and directed clinical programs at Walden 
House for the past 10 years and has imple­
mented evidence-based practices in resi­
dential and outpatient settings. Her areas 
of specialization include dual diagnosis, cul­
tural competency, and clinical skills. THIS ISSUE’S AUTHORS • 51 
SUZETTE GLASNER-EDWARDS, 
PH.D., is a licensed clinical psychologist 
and assistant research psychologist at the 
University of California, Los Angeles Inte­
grated Substance Abuse Programs. Her 
research interests include intervention devel­
opment for substance abusers with and with­
out co-occurring disorders. Currently, she 
is the principal investigator of a NIDA-
funded psychosocial clinical trial of inte­
grated cognitive-behavioral and motiva­
tional treatment strategies for stimulant users 
with co-occurring affective disorders. She 
is also examining pharmacological treat­
ment approaches for this population. 
DENNIS PAUL, PH.D., received his doc­
torate in biopsychology from the Univer­
sity of British Columbia and postdoctoral 
training in the Department of Neurology 
at the Memorial Sloan-Kettering Cancer 
Center in New York. He has been a fac­
ulty member of the Department of Phar­
macology at the Louisiana State University 
Health Sciences Center in New Orleans 
since 1990. His research interests include 
opioid receptor mechanisms in analgesia 
and drug abuse, and the development of 
novel drug therapies for neuropathic pain. 
JOHN ROLL, PH.D., is the director of the 
Washington Institute for Mental Health 
Research and Training at Washington State 
University. He is a vice-chair of the Wash­
ington State Governor’s Council on Sub­
stance Abuse, where he is in charge of the 
treatment subcommittee. Dr. Roll’s primary 
research interests are basic behavioral phar­
macology and the development of behav­
ioral interventions for substance abuse and 
related disorders. He has published numer­
ous articles, abstracts, and book chapters. 
HELEN SACKLER, PH.D., is a licensed 
clinical psychologist. She is a clinical instruc­
tor in the Department of Psychiatry at Yale 
University Medical School and serves as a 
clinical supervisor for pre- and postdoctoral 
psychology interns. She is also a consultant 
and clinical supervisor at the APT Founda­
tion, a substance abuse treatment agency. 
She has a private substance abuse treatment 
practice in New Haven, Connecticut. 
MARIA A. SULLIVAN, M.D., PH.D., is 
an associate professor of clinical psychiatry 
in the Division on Substance Abuse at the 
New York State Psychiatric Institute and 
Columbia University College of Physicians 
and Surgeons. Her research interests include 
developing pharmacological and behavioral 
treatments for nicotine and opioid depend­
ence, as well as for opioid abuse in indi­
viduals with chronic pain. She has published 
extensively on naltrexone and buprenor­
phine as treatments for opioid dependence, 
behavioral therapy for addiction, smoking 
cessation, the links between depression and 
addiction, and prescription opioid abuse. 
ROGER D. WEISS, M.D., is a professor 
of psychiatry at Harvard Medical School 
and clinical director of the Alcohol and Drug 
Abuse Treatment Program at McLean Hos­
pital. He has been the principal investiga­
tor on numerous grants from NIDA and 
the National Institute on Alcohol Abuse and 
Alcoholism, and is currently principal inves­
tigator of the Northern New England Node 
of the NIDA Clinical Trials Network, where 
he is leading a multisite national trial on the 
treatment of prescription opioid depend­
ence. He has authored numerous articles 
and book chapters, and has recently devel­
oped a new group therapy for patients with 
bipolar disorder and substance dependence.   